The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
 
Shanu Modi
Honoraria - GlaxoSmithKline; Novartis; Puma Biotechnology
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Macrogenics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Genentech; Seagen
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
Travel, Accommodations, Expenses - Daiichi Sankyo; Genentech
 
Fabrice Andre
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genomic Health; MSD; Novartis; Pfizer; Philips HealthWorks; Pierre Fabre; Pique; Puma Biotechnology; Roche; Sanofi; Synthon
Research Funding - AstraZeneca (Inst); Genentech (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Roche (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; Enzychem Lifesciences; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; Enzychem Lifesciences (Inst); ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Kyowha Kirin (Inst); Novartis (Inst)
 
Kenji Tamura
Research Funding - Daiichi Sankyo; Eisai; Lilly; Pfizer
 
Shuquan Chen
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Fumitaka Suto
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yusuke Kuwahara
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Caleb C. Lee
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yeon Hee Park
Honoraria - Merck; Novartis; Pfizer
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; Eisai; Pfizer
Travel, Accommodations, Expenses - Merck; Novartis